Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly Purchases 2,113 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly bought 2,113 shares of Precision BioSciences stock in a transaction that occurred on Friday, December 27th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $10,036.75. Following the completion of the transaction, the chief financial officer now directly owns 40,186 shares in the company, valued at $190,883.50. This represents a 5.55 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Precision BioSciences Stock Performance

Shares of Precision BioSciences stock opened at $3.81 on Thursday. The company has a 50 day moving average price of $6.59 and a 200 day moving average price of $8.51. The firm has a market capitalization of $29.23 million, a P/E ratio of 63.51 and a beta of 1.41. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $19.43.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Geode Capital Management LLC raised its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 at the end of the most recent quarter. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.